TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06270329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular training program
Description: Hotpack application TENS (transcutaneous electrical stimulation) Warm-up phase: bicycle ergometer (ten minutes)~Exercise phase:~core stabilization and postural control exercises postural orientation exercises lower extremity strengthening exercises functional exercises (balance and proprioception exercises using a balance board) Cool-down Phase

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy program
Description: Hotpack application TENS (transcutaneous electrical stimulation) Conventional physical therapy exercises (straight leg raises, knee flexor and extensor strengthening, hip muscle strengthening)
Study: NCT06119035

Intervention type: OTHER
Group type: OTHER
Intervention: Single dose of 75 grams glucose in 200ml water
Description: Consume single dose of 75 grams glucose in 200ml water
Study: NCT04764487

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KidneyPRO
Description: Web-application for symptoms assessment

Intervention type: OTHER
Group type: OTHER
Intervention: standard follow-up
Description: usual follow-up
Study: NCT05377411

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: During tDCS, a weak electrical current is applied to the scalp that penetrates skin, bone, CSF and the meninges to stimulate underlying cortical and subcortical tissue

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: During tDCS, a weak electrical current is applied to the scalp that penetrates skin, bone, CSF and the meninges to stimulate underlying cortical and subcortical tissue

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive training
Description: Cognitive Training (CT) will involve up to 10 hours of training over 2-weeks (10 days). CT employs a PositScience BrainHQ suite via its researcher portal. These tasks are web-based and multi-platform (i.e., Windows, Mac). Participants will be randomly assigned to training on 4 tasks focusing on working memory or 4 tasks focusing on attention/speed of processing.
Study: NCT05686954

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSO LOW
Description: Participants are provided a breakfast shake and a snack daily that delivers 10% of the participant's estimated energy needs as cottonseed oil for 28 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSO MID
Description: Participants are provided a breakfast shake and a snack daily that delivers 20% of the participant's estimated energy needs as cottonseed oil for 28 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSO HIGH
Description: Participants are provided a breakfast shake and a snack daily that delivers 30% of the participant's estimated energy needs as cottonseed oil for 28 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL
Description: Participants are provided a breakfast shake and a snack daily that delivers 10% of the participant's estimated energy needs as a mixture of oils that match the average American fat intake for 28 days.
Study: NCT02919189

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by fluorescent light lamps.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by fluorescent light lamps.
Study: NCT06033053

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-time fMRI neurofeedback from Turbo Brain voyager (TBV) 3.2
Description: The two groups will undergo the same paradigm while learning to modulate the vmPFC -amygdala pathway and the sham pathway.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Real-time fMRI neurofeedback from Turbo Brain voyager (TBV) 3.2
Description: The two groups will undergo the same paradigm while learning to modulate the vmPFC -amygdala pathway and the sham pathway.
Study: NCT05267288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib
Description: afatinib 40mg oral, bevacizumab 15mg/kg iv, every 21days, until progression disease, untolerated toxicities, or patient death.
Study: NCT05194865

Intervention type: DEVICE
Intervention: cardiac MRI
Description: assessment of the viability using CMR

Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention
Description: direct revascularization using PCI
Study: NCT06511050

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lumbrokinase
Description: Boluoke® brand lumbrokinase capsules will be taken daily for 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lumbrokinase
Description: Boluoke® brand lumbrokinase capsules will be taken daily for 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lumbrokinase
Description: Boluoke® brand lumbrokinase capsules will be taken daily for 6 weeks.
Study: NCT05755165

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Depression
Description: \~90-second selfie video of an adolescent discussing her history of depression, treatment, and recovery

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Depression, adjusted
Description: \~90-second selfie video of an adolescent discussing her history of depression, treatment, and recovery - and including explicit reference to the role of anti-Black racism as a contributing factor

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: \~90-second selfie video of an adolescent discussing everyday activities and interests, with no reference to depression or racism.
Study: NCT05410392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise intervention
Description: Home-based physical exercise with the use of a stationary recumbent style bike.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise intervention
Description: Home-based physical exercise with the use of a stationary recumbent style bike.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive exercise intervention
Description: Home-based cognitive exercise with the use of smartphone to complete cognitive activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive exercise intervention
Description: Home-based cognitive exercise with the use of smartphone to complete cognitive activities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Provision of general information about a variety of topics
Study: NCT04986579

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paxman Scalp Cooling System
Description: Cap attached to coolant lines connected to a refrigeration unit placed on scalp

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paxman Scalp Cooling System
Description: Cap attached to coolant lines connected to a refrigeration unit placed on scalp

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paxman Scalp Cooling System
Description: Cap attached to coolant lines connected to a refrigeration unit placed on scalp

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Intravenous Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: Intravenous Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sacituzumab govitecan
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Intravenous Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab deruxtecan
Description: Intravenous Infusion
Study: NCT06276231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Salbutamol 10mg nebulization over 5 minutes ( flow rate 5-7 liters).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal Saline
Description: Normal saline nebulization over 5 minutes ( flow rate 5-7 liters).
Study: NCT05377411

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: cognitive training
Description: Cognitive Training (CT) will involve up to 10 hours of training over 2-weeks (10 days). CT employs a PositScience BrainHQ suite via its researcher portal. These tasks are web-based and multi-platform (i.e., Windows, Mac). Participants will be randomly assigned to training on 4 tasks focusing on working memory or 4 tasks focusing on attention/speed of processing.
Study: NCT06276231

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diclofenac Injection
Description: 75 mg of Diclofenac intramuscular Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Injection
Description: 75 mg of Diclofenac intramuscular Injection
Study: NCT05367037

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PhysioVP
Description: The Physiological ventricular pacing is achieved by delivering a stimulus to a cardiac conduction structure, such as the bundle of His or left bundle branch of the His-Purkinje system, with a permanent lead. PhysioVP activates the heart through the native His-Purkinje conduction system, thus offering the most physiologic pacing approach to correct the PR interval and avoiding pacing-induced dyssynchrony. A specialized delivery sheath for His-Purkinje system pacing with appropriate or standard leads will be used. The atrial leads will be implanted in the right atrial appendage and will connect the leads to the standard dual-chamber PM. By continuously recording a 12-lead ECG, we determine whether cardiac conduction structure, such as the bundle of His or left bundle branch of the His-Purkinje system, will be achieved.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DDD-VPA
Description: In dual-chamber pacing with the addition of algorithms for ventricular pacing avoidance, also called managed ventricular pacing, the right ventricular (RV) lead is implanted in the myocardial right ventricular (septum or apex). In this pacing mode, the ventricular pacing is minimized by using algorithms for right ventricular pacing avoidance. Therefore, the RV leads will be implanted in the right ventricular myocardial sites (septum or apex) and standard bipolar active or passive fixation leads. In addition, the atrial leads will be implanted in the right atrial appendage and connect leads to the standard dual-chamber PM.
Study: NCT05577494

Intervention type: OTHER
Intervention: Questionnaire online
Description: Questionnaire online: all subjects will receive an online questionnaire and complete the Clinician Questionnaire.~Semi-structured interviews: semi-structured interviews are conducted with the clinician interviewers using the Clinician Interview Guide.~Focus group discussion: Focus group discussions are conducted with patients according to the Patient Focus Group Symposium Manual.

Intervention type: OTHER
Intervention: Questionnaire online
Description: Questionnaire online: all subjects will receive an online questionnaire and complete the Clinician Questionnaire.~Semi-structured interviews: semi-structured interviews are conducted with the clinician interviewers using the Clinician Interview Guide.~Focus group discussion: Focus group discussions are conducted with patients according to the Patient Focus Group Symposium Manual.
Study: NCT05121168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active bupivacaine 0.25% via an erector spinae plane perineural catheter
Description: Administration of bupivacaine 0.25% through a perineural catheter inserted into the erector spinae plane (programmed intermittent bolus of 21 mL every 4 hours and no patient-controlled bolus)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo normal saline via an erector spinae plane perineural catheter
Description: Administration of normal saline through a perineural catheter inserted into the erector spinae plane (programmed intermittent bolus of 21 mL every 4 hours and no patient-controlled bolus)
Study: NCT06003309

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS) - Fully Individualized iTBS
Description: Repetitive transcranial magnetic stimulation (rTMS) is a safe and effective treatment for TRD that is increasingly being used in clinical practice across the world. It's mechanism of action is based on Farady Law of electromagnetic induction where the magnetic field produced by TMS coil induces electric field in the neurons. In the Ind-iTBS, the coil placement and current amplitude will be provided using individualized E-field modelling and coordinate-based cortical targeting. The stimulation frequency will also be individualized according to EEG-derived TGC.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS) - targeted-iTBS
Description: Repetitive transcranial magnetic stimulation (rTMS) is a safe and effective treatment for TRD that is increasingly being used in clinical practice across the world. It's mechanism of action is based on Farady Law of electromagnetic induction where the magnetic field produced by TMS coil induces electric field in the neurons. In the targeted-iTBS, the coil placement and current amplitude will be provided using individualized E-field modelling and coordinate-based cortical targeting.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS) - Standard-iTBS
Description: Repetitive transcranial magnetic stimulation (rTMS) is a safe and effective treatment for TRD that is increasingly being used in clinical practice across the world. It's mechanism of action is based on Farady Law of electromagnetic induction where the magnetic field produced by TMS coil induces electric field in the neurons. The standard iTBS will be delivered with the typical 5Hz/50Hz patterned frequencies used in the FDA approved treatment protocol and stimulation will be delivered according to the Beam F3 targeting.
Study: NCT06111521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3537982
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3537982
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Administered orally
Study: NCT05102448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: 1. Tofacitinib 5mg twice a day for 12 months;~2. Basic treatment with prednisone: (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day (maximum 60mg/day). (2) Glucocorticoids tapering: glucocorticoids is tapered after two weeks treatment and is tapered 5mg each 2 weeks to 10mg qd in the first 6 months if patients were in inactive status based on the NIH disease activity criteria. During the 6th to 12th month, glucocorticoids is tapered 2.5mg each 4 weeks until 7.5mg qd if patients were in inactive status based on the NIH disease activity criteria.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: 1. Methotrexate (15mg each week) for 12 months~2. Basic treatment with prednisone: (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day (maximum 60mg/day). (2) Glucocorticoids tapering: glucocorticoids is tapered after two weeks treatment and is tapered 5mg each 2 weeks to 10mg qd in the first 6 months if patients were in inactive status based on the NIH disease activity criteria. During the 6th to 12th month, glucocorticoids is tapered 2.5mg each 4 weeks until 7.5mg qd if patients were in inactive status based on the NIH disease activity criteria.
Study: NCT03327129

Intervention type: PROCEDURE
Intervention: fMRI
Description: An fMRI scan will be conducted to collect neuroimaging data. The scanning session will consist of a structural MRI, followed by resting state and task-based functional MRI protocol.

Intervention type: PROCEDURE
Intervention: fMRI
Description: An fMRI scan will be conducted to collect neuroimaging data. The scanning session will consist of a structural MRI, followed by resting state and task-based functional MRI protocol.
Study: NCT06111521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered IV
Study: NCT04949464

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo LDCT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention
Description: Use Positively Smoke Free - Mobile
Study: NCT05314478

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous laryngoscopy during exercise test using the HALOS headgear
Description: The participant will undergo the CLE test following standard clinical practice.~The order of events of the aspects of the investigation related to the headgear will be:~1. The headgear is prepared for use.~2. The headgear is fitted onto the participant's head.~3. The endoscope is inserted into the participant.~4. The endoscope is fitted onto the headgear.~5. The CLE test is carried out.~6. The endoscope is removed from the headgear.~7. The endoscope is removed from the participant.~8. The headgear is removed from the participant.~9. The headgear is cleaned and stored.
Study: NCT06482749

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: Repeated transcranial magnetic stimulation (rTMS) over left dorsolateral prefrontal cortex (DLPFC) for a 5-day period (1 day before surgery and 4 consecutive days after surgery, twice daily \[10-12 am and 4-6 pm\]). Parameters of rTMS: 8 shaped coil, 10 Hz, 80% resting motor threshold (RMT), 2000 pulses (5s × 40 trains, 25 s interval), 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham repeated transcranial magnetic stimulation (rTMS) over left dorsolateral prefrontal cortex (DLPFC) for a 5-day period (1 day before surgery and 4 consecutive days after surgery, twice daily \[10-12 am and 4-6 pm\]). Parameters of rTMS: 8 shaped sham coil, 10 Hz, 80% resting motor threshold (RMT), 2000 pulses (5s × 40 trains, 25 s interval), 20 minutes.
Study: NCT05515198

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: Patients will be provided educational opportunities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: Patients will be provided educational opportunities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: Patients will be provided educational opportunities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse Navigation
Description: A nurse navigator will work with the participants to help them navigate the care pathway. The navigator will provide education and recommendations for treatment options.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse Navigation
Description: A nurse navigator will work with the participants to help them navigate the care pathway. The navigator will provide education and recommendations for treatment options.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ChatBot
Description: A ChatBot will allow participants to directly and privately communicate through a smartphone (or other device) with an artificial intelligence-driven ChatBot, also known as a conversational agent, that will provide education and encouragement to manage their symptoms.
Study: NCT06070441

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: One-week, three sessions in alternate days, outpatient supervised education on how to perform the exercises at home

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: One-week, three sessions in alternate days, outpatient supervised education on how to perform the exercises at home

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chatbot
Description: 12 week- intervention consisting of messages with an explanatory video of each exercise indicating how to do it and how many repetitions to perform

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise, usual care
Description: 12 week- intervention. Printed sheets indicating how to exercises and how many repetitions to perform
Study: NCT05343000

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation (PR) system
Description: Technology to facilitate remote health coaching through PAP management, sleep scheduling, sleep duration, diet, exercise, medication and more. The tablet and sensors upload the patient's activities, physiological data, and answers to the daily self-report questions to a secure website. This website also allows health coaches to view patient data via overview, weekly, daily, and trend reports. Health coaches call patients regularly to celebrate progress, assist with any issues, and set new goals.
Study: NCT05513300

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: 12 weeks of exercise training, 3 times per week, \~1h long

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: 12 weeks of exercise training, 3 times per week, \~1h long
Study: NCT05685758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FTP-based therapeutic mobile-app
Description: Participants are expected to play games within the mobile app and complete the available daily levels of 4 out of 5 games on at least 4 days per week for 8 weeks.
Study: NCT05436275

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: CM310
Description: 300 mg every two weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: once every two weeks
Study: NCT06406790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CraniSeal
Description: CraniSeal is a PEG Dural Sealant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DuraSeal
Description: DuraSeal is a PEG Dural Sealant